Genetic diagnosis (PMDA panel)
GeneticBlood samples for DNA study
Recruiting
NCT Number: NCT04261127
Validation of the RADIAL Algorithm for Diagnosis of Autosomal Recessive Cerebellar Ataxia
RADIAL is an algorithm which has been developed following a review of the literature on 67 autosomal recessive cerebellar ataxias (ARCA) and personal clinical experience. Frequency and specificity of each feature were defined for each autosomal recessive cerebellar ataxia, and corresponding prediction scores were assigned. Clinical and paraclinical features of patients are entered into the algorithm, and a patient's total score for each ARCA is calculated, producing a ranking of possible diagnoses. Sensitivity and specificity of the algorithm were assessed by blinded analysis of a multinational cohort of 834 patients with molecularly confirmed autosomal recessive cerebellar ataxia. The performance of the algorithm was assessed versus a blinded panel of autosomal recessive cerebellar ataxia experts. The correct diagnosis was ranked within the top 3 highest-scoring diagnoses at a sensitivity and specificity of >90% for 84% and 91% of the evaluated genes, respectively. Mean sensitivity and specificity of the top 3 highest-scoring diagnoses were 92% and 95%, respectively. Our aim is now to validate in a prospective cohort of ARCA, the performance of RADIAL to predict the correct genetic diagnosis.
Recruiting
Interested in participating?
Request InfoKey information
Conditions
Age range
5 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
CHU de Besancon- Neurology, Besançon, France
Loading trial locations.
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- For patients:
- Patient, male or female, over 5 years old (no upper age limit)
- Patient with cerebellar ataxia who started before the age of 40
- Patient with a family history compatible with autosomal recessive inheritance (sporadic case, consanguinity, several cases in siblings)
- Patient in which an acquired cause of cerebellar ataxia has been excluded
- Patient whose genetic diagnosis is unknown (NB: patients with a known negative result for the Friedreich's disease gene are eligible for inclusion))
- For patients over 18 years old: patient speaking and reading French, able to give a signed and dated informed consent to participate in the study.
Patients who have reached the age of majority and whose DNA has been banked and who have signed a consent form authorizing the subsequent use of this DNA for research purposes, including genetic analysis of cerebellar ataxias or associated pathologies, and for whom the RADIAL information sheet can be completed in full, are eligible for inclusion.
- For patient under 18 years old: Tutor or person with parental authority must speak French and be able to give a signed and dated informed consent for the minor patient.
Patients who are minors, whose DNA has been banked and for whom the parental authority has signed a consent form authorizing the subsequent use of this DNA for research purposes, including genetic analysis of cerebellar ataxias or associated pathologies, and for whom the RADIAL information sheet can be completed, are eligible.
- Patient affiliated to the French national health insurance
- For relatives:
- Male or female, over 18 years old (no upper age limit)
- Biological father or mother of a patient included in RADIAL-VALID research protocol
- (for prospective inclusion only) To be available for a visit to the participating center where the child is being followed
- Speaking and reading French, able to give a signed and dated informed consent to participate in the study
- Subject affiliated to the French national health insurance
Exclusion criteria
- For patients:
- Patient in whom targeted sequencing of a panel of PMDA genes and/or exome/genome sequencing have already been performed.
- For patients and related:
- Subject of a legal protection measure
- Subject in exclusion period (determined by previous or current study)
Treatment and study plan
Use of RADIAL algorithm
Diagnostic TestRADIAL card filling (contains clinical and biological data)
Primary outcomes
-
Percentage of patients for whom the final genetic diagnosis is in the top 3 of the diagnoses proposed by the RADIAL algorithm (corresponding to the diseases with the 3 highest score given by the algorithm).
Time frame: At final visit (depending of genetic results from 2 to 24 month maximum after inclusion visit)
The final diagnosis will be established after a genetic analysis and a medical interpretation of the results by geneticists.
Secondary outcomes
-
Percentage of patients for whom the final genetic diagnosis is the first diagnosis proposed by the RADIAL algorithm (corresponding to the disease with the highest score given by the algorithm).
Time frame: At final visit (depending of genetic results from 2 to 24 month maximum after inclusion visit)
-
Comparison of interpretation times by the clinical-genetic team (genetic and clinical data) with and without the help of the RADIAL algorithm
Time frame: At final visit (depending of genetic results from 2 to 24 month maximum after inclusion visit)
Randomization is a methodological refinement that is only useful for this secondary endpoint (does not relate to the primary endpoint). The clinical and paraclinical data of all patients will be treated in the same way, and randomization concerns only the use of RADIAL made by the data biologist in sample processing. There is therefore no randomization of subjects but only of genetic results.
At the genetic study stage (Panel PMDA panel), for the patient group randomized "with RADIAL results", the interpretation of genetic data (and in particular of the different variants found) will be done aware of the results given by RADIAL, and in the randomized group "without results RADIAL ", the analysis of the genetic data will be done in the absence of knowledge of the results provided by RADIAL.
-
Comparison of the satisfaction score given by the clinical-genetic team in the interpretation of data with and without the help of the RADIAL algorithm
Time frame: At final visit (depending of genetic results from 2 to 24 month maximum after inclusion visit)
Randomization is a methodological refinement that is only useful for this secondary endpoint (does not relate to the primary endpoint). The clinical and paraclinical data of all patients will be treated in the same way, and randomization concerns only the use of RADIAL made by the data biologist in sample processing. There is therefore no randomization of subjects but only of genetic results.
At the genetic study stage (Panel PMDA panel), for the patient group randomized "with RADIAL results", the interpretation of genetic data (and in particular of the different variants found) will be done aware of the results given by RADIAL, and in the randomized group "without results RADIAL ", the analysis of the genetic data will be done in the absence of knowledge of the results provided by RADIAL.
-
Influence of RADIAL on genetic diagnosis: percentage of patients whose diagnosis has been reviewed after the clinical-genetic team has learned of the results proposed by RADIAL
Time frame: At final visit (depending of genetic results from 2 to 24 month maximum after inclusion visit)
Randomization is a methodological refinement that is only useful for this secondary endpoint (does not relate to the primary endpoint). The clinical and paraclinical data of all patients will be treated in the same way, and randomization concerns only the use of RADIAL made by the data biologist in sample processing. There is therefore no randomization of subjects but only of genetic results.
At the genetic study stage (Panel PMDA panel), for the patient group randomized "with RADIAL results", the interpretation of genetic data (and in particular of the different variants found) will be done aware of the results given by RADIAL, and in the randomized group "without results RADIAL ", the analysis of the genetic data will be done in the absence of knowledge of the results provided by RADIAL.
-
Percentage of patients for whom the genome analysis will have detected a new gene.
Time frame: At final visit (depending of genetic results from 2 to 24 month maximum after inclusion visit)
If no diagnosis is established after the PMDA + RADIAL analyzes, additional genetic analyzes will be carried out for patient and for relatives (genome). These new analyzes should help to define the diagnosis of the patient.
Study contacts
Contact information is provided by the study sponsor or research team.
Sponsors and collaborators
Lead sponsor
University Hospital, Strasbourg, France
Other
Registry information
Acronym: RADIAL-VALID
Important dates
- Study start
- 2021
- Primary completion
- 2029
- Study completion
- 2029
- First posted
- Feb 7, 2020
- Registry last updated
- Aug 27, 2025
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Recruiting
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
NCT01793168
1p36 Deletion Syndrome, 3-Methylglutaconic Aciduria, Type V
Sioux Falls, South Dakota, United States
View Trial Details